All In Biotech

Drug Trial Radar · NCT06693934

Jockey Club Precision Prevention Programme on Young Onset Diabetes

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9,000

Planned (sponsor's estimate)

Start

Nov 23, 2024

Primary completion

Oct 2027

Study completion May 2028

Sponsor

Lead sponsor
Juliana CN ChanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chinese University of Hong Kong; St. James' Settlement; Asia Diabetes Foundation
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a community-based implementation program consisting of multiple components delivered by a multidisciplinary team to detect and prevent young onset diabetes with precision and value using biogenetic markers, digital tools, integrated care through public private partnership. Adults aged between 18 and 44 (inclusive) without known diabetes and with at least one risk factor for diabetes will undergo a saliva DNA and capillary blood test and complete a questionnaire. Depending on their risk levels, participants will be stratified to high risk and low risk progressors to diabetes. The high risk progressors will undergo annual oral glucose tolerance test to detect diabetes and impaired glucose tolerance (IGT). All participants will receive a personalized report indicating their genetic and modifiable risk explained by nurses or doctors. All participants will be offered regular access to webinars for education and empowerment for 2 years. The high risk group will additionally receive a 2-year risk-stratified intervention with different combinations of care interventions. These include clinical and laboratory assessment for comprehensive evaluation of cardiovascular-kidney-metabolic risks, medical and nurse consultations, empowerment by health messages, webinars, face-to-face workshops, subsidies for medications and self-monitoring tools (e.g. CGM devices, weighing scale) to motivate behavioural change. The outcomes will be analysed within the REAIM framework (reach, effectiveness, adoption, implementation and maintenance), progresssion to prediabetes or diabetes, patient reported outcomes and cost effectiveness.

Conditions

  • Diabetes
  • Pre Diabetes
  • Hypertension
  • Dyslipidemia
  • Obesity

Interventions

  • Risk assessment with biogenetic and clinical test to predict diabetes riskGenetic

    All participants will undergo genetic test and clinical measurement including body weight, body height, blood pressure, waist circumference and capillary blood glucose to predict diabetes risk with report explanation by doctors (for high risk, IGT and DM) and nurses (low risk). Genetic report will be updated annually for high risk and IGT group using updated clinical factors (e.g. age, BMI, BP).

  • Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factorsDiagnostic test

    High risk progressors will undergo OGTT and measurement of CKM factors at baseline. In those without IGT or diabetes, they will undergo OGTT and CKM risk factor assessment annually for 2 years. The IGT group will additionally have measurement of beta-cell function (HOMA indexes) and the DM group will additionally have autoimmune marker measurement.

  • MedicationDrug

    Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.

  • Continuous glucose monitoring (CGM) devices and/or weighing scaleDevice

    All high risk progressors will be given subsidized weighing scale and low-intensity laboratory assessments, nurse and doctor consultation, regular WhatsApp messages and webinars for 2 years. The IGT and DM group will receive additional subsidized CGM devices for empowerment.

  • Visit to family doctor with nurse educationBehavioral

    All participants in high risk, IGT and diabetes groups will have regular follow-up by family doctors and nurses.

  • Joint Asia Diabetes Evaluation (JADE) assessmentDiagnostic test

    Participants found to have diabetes on OGTT will undergo annual JADE assessment which include eye/foot/urine/blood tests with issue of a personalized JADE report. The JADE Program is a quality improvement program to improve self management and inform shared decision making between doctor and patient.

  • Education webinars, workshops and health messagesBehavioral

    All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of prediabetes or diabetes in the high and low risk progressor groupsTime frame: From the date of recruitment until the end of the programme in 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asia Diabetes Foundation

    Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.